March 28 (Reuters) - The European Union's drugs regulator on Friday rejected Eli Lilly's LLY.N Alzheimer's drug Kisunla, saying the risk of serious brain swelling did not outweigh the treatment's small impact on slowing cognitive decline.
(Reporting by Mariam Sunny and Padmanabhan Ananthan in Bengaluru; Editing by Shreya Biswas and Sriraj Kalluvila)
((Padmanabhan.Ananthan@thomsonreuters.com Mariam.ESunny@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.